1. Home
  2. BVS vs DBVT Comparison

BVS vs DBVT Comparison

Compare BVS & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BVS
  • DBVT
  • Stock Information
  • Founded
  • BVS 2011
  • DBVT 2002
  • Country
  • BVS United States
  • DBVT France
  • Employees
  • BVS N/A
  • DBVT N/A
  • Industry
  • BVS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BVS Health Care
  • DBVT Health Care
  • Exchange
  • BVS Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • BVS 476.3M
  • DBVT 464.0M
  • IPO Year
  • BVS 2021
  • DBVT N/A
  • Fundamental
  • Price
  • BVS $6.56
  • DBVT $14.05
  • Analyst Decision
  • BVS Strong Buy
  • DBVT Buy
  • Analyst Count
  • BVS 4
  • DBVT 5
  • Target Price
  • BVS $13.75
  • DBVT $15.85
  • AVG Volume (30 Days)
  • BVS 210.8K
  • DBVT 181.7K
  • Earning Date
  • BVS 11-04-2025
  • DBVT 10-28-2025
  • Dividend Yield
  • BVS N/A
  • DBVT N/A
  • EPS Growth
  • BVS N/A
  • DBVT N/A
  • EPS
  • BVS 0.03
  • DBVT N/A
  • Revenue
  • BVS $564,142,000.00
  • DBVT $5,502,000.00
  • Revenue This Year
  • BVS N/A
  • DBVT $1,743.46
  • Revenue Next Year
  • BVS $7.22
  • DBVT $1,044.34
  • P/E Ratio
  • BVS $236.89
  • DBVT N/A
  • Revenue Growth
  • BVS 5.08
  • DBVT N/A
  • 52 Week Low
  • BVS $5.81
  • DBVT $2.21
  • 52 Week High
  • BVS $14.38
  • DBVT $18.00
  • Technical
  • Relative Strength Index (RSI)
  • BVS 42.70
  • DBVT 49.21
  • Support Level
  • BVS $6.66
  • DBVT $13.89
  • Resistance Level
  • BVS $7.15
  • DBVT $15.97
  • Average True Range (ATR)
  • BVS 0.27
  • DBVT 1.10
  • MACD
  • BVS -0.03
  • DBVT -0.40
  • Stochastic Oscillator
  • BVS 6.52
  • DBVT 8.33

About BVS Bioventus Inc.

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: